Compare FIGR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIGR | AMRX |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.4B |
| IPO Year | 2025 | 2018 |
| Metric | FIGR | AMRX |
|---|---|---|
| Price | $23.18 | $21.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $51.56 | $23.00 |
| AVG Volume (30 Days) | ★ 4.2M | 3.1M |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | ★ 0.53 | 0.37 |
| Revenue | ★ $506,865,000.00 | N/A |
| Revenue This Year | $109.25 | $4.56 |
| Revenue Next Year | $36.72 | $9.33 |
| P/E Ratio | ★ $42.81 | $57.89 |
| Revenue Growth | ★ 48.69 | N/A |
| 52 Week Low | $21.78 | $9.99 |
| 52 Week High | $78.00 | $21.43 |
| Indicator | FIGR | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.90 | 65.27 |
| Support Level | N/A | $16.59 |
| Resistance Level | $34.54 | N/A |
| Average True Range (ATR) | 1.71 | 0.60 |
| MACD | -0.25 | 0.12 |
| Stochastic Oscillator | 13.19 | 82.70 |
Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.